Exclusive Summary

• Secure the multi-billion-dollar PARP inhibitor market by locking in distribution rights ahead of the originator's cascading core patent expiries post-2024.
• Tap into the massive, sustained demand for four high-incidence cancers (ovarian, breast, prostate, pancreatic) with a WHO EML-listed, NCCN 1L maintenance standard-of-care.
• The high barrier to entry for HPAPI tablet manufacturing eliminates low-end competition, while the 150mg tablet dramatically reduces pill burden, offering strong market differentiation.
• Disrupt the exhorbitant pricing of the originator with a highly cost-effective generic alternative, fully supported by CTD dossiers to accelerate rapid local registration and emerging market penetration.